成都招聘

1. 根据病人情况，制定详细的治疗方案；
2. 耐心、清楚地向病人解释病情及治疗方案，保证病人充分理解和同意；
3. 根据医院要求，规范、详细书写病历和处方，完善病历档案
4. 认真执行各项规章制度和技术操作常规
5. 主动学习和运用国内外先进医学科学技术、开展新技术、新疗法；
任职要求：
1.吃苦耐劳，热爱医疗卫生事业，具有良好的专业素质和爱岗敬业精神。
2.身心健康，品貌端正，体检合格，能够胜任聘用岗位的需要。
3.取得应聘岗位所需的执业资格证书及职称资格证书。
4.具有三甲医院从业经历，优秀的副高职称及以上专家人才条件面议。

中健瑞杰生物科技股份有限公司正在入驻四川省自贸区天府生命科学园区内，注册资金1.亿元，以前沿医学生物技术为核心，以再生医学、特需医疗为平台。集科研、临床、产品服务三位一体的精准医疗高科技企业。
CHR Biotechnology Co., Ltd is entering the Tianfu Life Science Park in the Sichuan Free Trade Zone, with a registered capital of 100 million yuan, with cutting-edge medical biotechnology as the core, regenerative medicine and special-needed medicine as the platform. CHR is a precision medical high-tech company integrating scientific research, clinical practice, and product services.
公司致力于生物医学技术临床研究、高端生物产品服务、精准医疗、细胞存储四大业务领域。注重夯实产业基础，强化各项体系建设，秉承“科技创新为企业***生产力”理念，汇聚国内外生物医疗领域高尖端科技专家及人才，引进行业先进的实验室设备，不断加大科研投入。目前筹备自主研发多项干细胞技术临床应用实验，力争生物技术及再生医学领域达到国际领先水平。
CHR is committed to the four major business areas including biomedical technology clinical research, high-end biological product services, precision medicine, and cell storage. We focus on consolidating the industrial foundation, strengthening the construction of various systems, adhering to the concept of "Science and technology are the primary productive forces", gathering high-tech experts and talents in the biomedical field in China and abroad, introducing advanced laboratory equipment in the industry, and continuously increasing investment in scientific research. We are currently preparing to independently research and develop a number of clinical application experiments of stem cell technology, and strive to take the world's leading position in the fields of biotechnology and regenerative medicine.
公司权威生物科研专家团队、联合国家卫健委批准的知名三甲医院开展临床研究。以前沿生物医疗技术成果应用为依托。
Relying on the application of cutting-edge biomedical technology achievements, CHR authoritative biological scientific research expert team will carry out clinical research in conjunction with well-known tertiary hospitals approved by the National Health Commission.
公司未来主要业务和研究内容：
Business Scope and Research Directions
1、细胞制备技术及质控体系研发：将建立符合GLP、cGMP及cGTP标准的细胞制备技术平台，开展包括干细胞制剂及应用的标准化研究，形成一整套完备的细胞制备和质控技术体系。
1. Research and development of cell preparation technology and quality control system. A cell preparation technology platform that complies with GLP, cGMP and cGTP standards will be established, and standardized research including stem cell preparations and applications will be carried out to form a complete set of cell preparation and quality control technology systems.
2、细胞存储体系：将开发以干细胞（脐带血造血干细胞、脐带间充质干细胞、***间充质干细胞、脂肪间充质干细胞等）和免疫细胞（外周血NK、CIK、DC、Car-T等）存储为核心的生物技术平台建设，打造区域性细胞存储基地。
2. Cell storage system. A biotechnology platform concentrates on the storage of stem cells (umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose-derived mesenchymal stem cells, etc.) and immune cells (peripheral blood NK, CIK, DC, Car-T, etc.) will be developed and constructed to build a regional cell storage base.
3、细胞产品体系：将自主研发具有独立知识产权的细胞制备上下游相关产品的产供销业务，包括干细胞药物备案、美妆相关产品的商品化和市场销售等。
3. Cell product system. Independently research and develop the cell preparation production, up-and downstream supply and marketing business with independent intellectual property rights, including the filing of stem cell drugs, the commercialization and market sales of beauty-related products.
4、细胞与分子临床检验体系：将建立基于常规五大检验技术体系为基础的、以细胞与分子临床检验为特色的研究型临床检验体系。
4. Cellular and molecular clinical testing system. A research-based clinical testing system featuring cellular and molecular clinical testing based on the 5 conventional testing technology systems will be established.
5、个体化健康管理和保健服务：以健康大数据为基础、生物统计学为手段，从基因和细胞水平探求个性化精准医学、解析人体健康奥秘，建立专业化健康服务平台。
5. Individualized health management and health services. Based on health big data and biostatistics, we will explore personalized precision medicine at the genetic and cellular level, analyze the mysteries of human health, and establish a professional health service platform.
6、干细胞临床转化研究：公司着眼干细胞临床转化，聚焦缺血性脑卒中、糖尿病和骨关节炎等疾病干细胞治疗，将与四川省内外的多家三甲医院开展干细胞临床转化研究。
6. Stem cell clinical transformation research. Focusing on the clinical transformation of stem cells, as well as stem cell treatment for diseases such as ischemic stroke, diabetes and osteoarthritis, it will conduct stem cell clinical transformation research with many top three hospitals in Sichuan Province.